Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE0006632003
Thu, 23.03.2023
MorphoSys AG
NOT FOR DISTRIBUTION IN OR INTO, OR TO ANY PERSON LOCATED OR RESIDENT IN, THE UNITED STATES OF AMERICA, ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES OF AMERICA OR THE DISTRICT OF COLUMBIA (THE "UNITED STATES"), AUSTRALIA, SOUTH AFRICA, JAPAN OR IN OR INTO ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLI [ … ]
Thu, 23.03.2023
MorphoSys AG
NOT FOR DISTRIBUTION IN OR INTO, OR TO ANY PERSON LOCATED OR RESIDENT IN, THE UNITED STATES OF AMERICA, ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES OF AMERICA OR THE DISTRICT OF COLUMBIA (THE "UNITED STATES"), AUSTRALIA, SOUTH AFRICA, JAPAN OR IN OR INTO ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLI [ … ]
Wed, 15.03.2023
MorphoSys AG
Media Release
Planegg/Munich, Germany, March 15, 2023
MorphoSys AG Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Topline data from the Phase 3 MANIFEST-2 study expected in early 2024
Monjuvi® U.S. net product sales of US$ 25.3 million (€ 24.7 million) for the fourth quarter of 2022 and US$ 89.4 milli [ … ]
Wed, 15.03.2023
MorphoSys AG
Media Release
Planegg/Munich, Germany, March 15, 2023
MorphoSys AG Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Topline data from the Phase 3 MANIFEST-2 study expected in early 2024
Monjuvi® U.S. net product sales of US$ 25.3 million (€ 24.7 million) for the fourth quarter of 2022 and US$ 89.4 milli [ … ]
Tue, 14.03.2023
MorphoSys AG
Media Release
Planegg/Munich, Germany, March 14, 2023
Lucinda Crabtree to Join MorphoSys as Chief Financial Officer
MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that Lucinda Crabtree, Ph.D., will join MorphoSys as Chief Financial Officer and member of the Management Board, succeeding Sung Lee. She will start in the third quarter 2023 a [ … ]
Tue, 14.03.2023
MorphoSys AG
Media Release
Planegg/Munich, Germany, March 14, 2023
Lucinda Crabtree to Join MorphoSys as Chief Financial Officer
MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that Lucinda Crabtree, Ph.D., will join MorphoSys as Chief Financial Officer and member of the Management Board, succeeding Sung Lee. She will start in the third quarter 2023 a [ … ]
Thu, 09.03.2023
MorphoSys AG
Conference Call Alert
Planegg/Munich, Germany, March 9, 2023
Invitation to MorphoSys’ Full Year Results 2022 Conference Call on March 16, 2023
MorphoSys AG (FSE: MOR; NASDAQ: MOR) will publish its results for the financial year 2022 on March 15, 2023 at 09:00 pm CET (08:00 pm GMT; 04:00 pm EDT).
MorphoSys' Management team will host a confe [ … ]
Thu, 09.03.2023
MorphoSys AG
Conference Call Alert
Planegg/Munich, Germany, March 9, 2023
Invitation to MorphoSys’ Full Year Results 2022 Conference Call on March 16, 2023
MorphoSys AG (FSE: MOR; NASDAQ: MOR) will publish its results for the financial year 2022 on March 15, 2023 at 09:00 pm CET (08:00 pm GMT; 04:00 pm EDT).
MorphoSys' Management team will host a confe [ … ]
Thu, 02.03.2023
MorphoSys AG
Media Release
Planegg/Munich, Germany, March 2, 2023
MorphoSys Stops Work and Operations on Pre-Clinical Research Programs
MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that the company will stop work and operations on its pre-clinical research programs to optimize its cost structure. While the data from these pre-clinical programs [ … ]
Thu, 02.03.2023
MorphoSys AG
Media Release
Planegg/Munich, Germany, March 2, 2023
MorphoSys Stops Work and Operations on Pre-Clinical Research Programs
MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that the company will stop work and operations on its pre-clinical research programs to optimize its cost structure. While the data from these pre-clinical programs [ … ]